Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.

Szczegóły
Abstrakt

Tytuł:: Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.
Autorzy:: Wei J; Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui Province, China.
Yao T; Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui Province, China.
Wang Y; Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui Province, China.
Li L; Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui Province, China.
Pan C; Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui Province, China.
Zhang N; Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui Province, China. .
Źródło:: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2019 Feb; Vol. 21 (2), pp. 232-238. Date of Electronic Publication: 2018 Jul 02.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: <2010- >: Milan : Springer Italia
Original Publication: Barcelona, Spain : Doyma, c2005-
MeSH Terms:: Adenocarcinoma/*pathology
Adenocarcinoma/*therapy
Neoplasm Staging/*methods
Stomach Neoplasms/*pathology
Stomach Neoplasms/*therapy
Adenocarcinoma/classification ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant/mortality ; Drug Combinations ; Female ; Gastrectomy/mortality ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoadjuvant Therapy/mortality ; Oxaliplatin/administration & dosage ; Oxonic Acid/administration & dosage ; Prognosis ; Retrospective Studies ; Stomach Neoplasms/classification ; Tegafur/administration & dosage
References:: World J Gastroenterol. 2004 Dec 1;10(23):3405-8. (PMID: 15526356)
Ann Surg Oncol. 2005 Dec;12(12):981-7. (PMID: 16244801)
N Engl J Med. 2006 Jul 6;355(1):11-20. (PMID: 16822992)
N Engl J Med. 2008 Jul 31;359(5):453-62. (PMID: 18669424)
Ann Surg Oncol. 2010 Nov;17(11):3053-8. (PMID: 20645013)
J Huazhong Univ Sci Technolog Med Sci. 2010 Aug;30(4):530-5. (PMID: 20714884)
Onkologie. 2011;34(12):682-6. (PMID: 22156447)
Ann Surg Oncol. 2012 Jun;19(6):1918-27. (PMID: 22246426)
J Clin Oncol. 2012 Jul 1;30(19):2327-33. (PMID: 22585691)
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):e585-92. (PMID: 22975616)
Acta Oncol. 2013 Nov;52(8):1751-9. (PMID: 23317142)
Am J Surg. 2014 Apr;207(4):555-65. (PMID: 24124661)
Oncol Lett. 2013 Dec;6(6):1693-1700. (PMID: 24260064)
J Clin Oncol. 2014 Mar 1;32(7):627-33. (PMID: 24470012)
PLoS One. 2014 May 08;9(5):e96455. (PMID: 24811256)
BMC Surg. 2014 May 16;14:29. (PMID: 24886548)
PLoS One. 2014 Sep 11;9(9):e107061. (PMID: 25211331)
CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787)
Surg Oncol. 2015 Jun;24(2):84-8. (PMID: 25912951)
Br J Surg. 2015 Nov;102(12):1500-5. (PMID: 26398912)
World J Gastroenterol. 2015 Dec 21;21(47):13294-301. (PMID: 26715812)
Springerplus. 2016 Jun 16;5(1):728. (PMID: 27375997)
Cancer Med. 2016 Oct;5(10):2773-2780. (PMID: 27666138)
J Gastric Cancer. 2016 Sep;16(3):161-166. (PMID: 27752393)
Dig Liver Dis. 2017 May;49(5):552-556. (PMID: 28179095)
Med Oncol. 2017 Aug;34(8):139. (PMID: 28707042)
Contributed Indexing:: Keywords: Gastric cancer; Independent prognostic factor; Multivariate analysis; Prognosis; Survival rate
Substance Nomenclature:: 0 (Drug Combinations)
04ZR38536J (Oxaliplatin)
150863-82-4 (S 1 (combination))
1548R74NSZ (Tegafur)
5VT6420TIG (Oxonic Acid)
Entry Date(s):: Date Created: 20180704 Date Completed: 20190514 Latest Revision: 20200225
Update Code:: 20240105
DOI:: 10.1007/s12094-018-1913-5
PMID:: 29968135
: Czasopismo naukowe

Full Text Finder

Aim: To study the prognostic factors of gastric cancer (GC) patients who were classified with stage III disease according to the newest TNM classification.
Methods: This study retrospectively enrolled 279 patients who underwent radical gastrectomy from January 2012 to December 2014 at our hospital and who were diagnosed with stage III GC according to the new 8th edition of the TNM classification. The patient data that were collected included age, sex, pathological parameters, survival, lymph node ratio, neo-adjuvant chemotherapy with oxaliplatin and S-1, and operation type. The characteristics, survival, and prognostic factors of the patients were analyzed by univariate and multivariate analyses.
Results: The median OS of the patients after curative surgery was 19 months, and the 3-year survival rate (3-YSR) was 25.3%. A univariate analysis showed that tumor location (P = 0.01), neo-adjuvant chemotherapy (P = 0.005), pathological T stage (P = 0.002), pathological N stage (P < 0.001), lymph node ratio (LNR) (P < 0.001), and operation type (P = 0.032) were significantly associated with overall survival. A multivariate analysis revealed that neo-adjuvant chemotherapy (P = 0.009), pathological T stage (P = 0.012), and LNR (P < 0.001) were independent prognostic factors.
Conclusions: Neo-adjuvant chemotherapy, pathological T stage, and LNR were independent prognostic factors for the overall survival of patients with stage III GC. The neo-adjuvant chemotherapy with oxaliplatin and S-1 can be used for the patients to improve their survival.

Informacja